Akari Therapeutics (AKTX)
1.08
-0.11 (-9.24%)
At close: Apr 04, 2025, 2:34 PM
-9.24% (1D)
| Bid | 1.05 |
| Market Cap | 13.18M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.58 |
| PE Ratio (ttm) | -0.42 |
| Forward PE | -0.39 |
| Analyst | n/a |
| Ask | 1.14 |
| Volume | 13,555 |
| Avg. Volume (20D) | 28,129 |
| Open | 1.16 |
| Previous Close | 1.19 |
| Day's Range | 1.05 - 1.16 |
| 52-Week Range | 0.85 - 4.40 |
| Beta | 0.58 |
About AKTX
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous p...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 6, 2014
Employees 9
Stock Exchange NASDAQ
Ticker Symbol AKTX
Website https://www.akaritx.com
2 weeks ago
+20%
Akari Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
